Victory Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $80.2M | Sell |
253,764
-49,460
| -16% | -$11.7M | 0.05% | 389 |
|
|
2026
Q1 | $60.5M | Buy |
303,224
+46,814
| +18% | +$9.26M | 0.04% | 450 |
|
|
2025
Q4 | $48.5M | Buy |
256,410
+1,605
| +0.6% | +$308K | 0.03% | 557 |
|
|
2025
Q3 | $45.1M | Buy |
254,805
+221,996
| +677% | +$33M | 0.03% | 596 |
|
|
2025
Q2 | $3.73M | Buy |
32,809
+5,131
| +19% | +$548K | ﹤0.01% | 1401 |
|
|
2025
Q1 | $2.91M | Buy |
27,678
+13,456
| +95% | +$1.52M | ﹤0.01% | 1439 |
|
|
2024
Q4 | $1.52M | Buy |
14,222
+200
| +1% | +$22.6K | ﹤0.01% | 1612 |
|
|
2024
Q3 | $1.4M | Buy |
14,022
+6,206
| +79% | +$625K | ﹤0.01% | 1629 |
|
|
2024
Q2 | $659K | Sell |
7,816
-1,210
| -13% | -$96.3K | ﹤0.01% | 1891 |
|
|
2024
Q1 | $660K | Sell |
9,026
-12,359
| -58% | -$911K | ﹤0.01% | 1896 |
|
|
2023
Q4 | $1.53M | Buy |
21,385
+3,976
| +23% | +$235K | ﹤0.01% | 1528 |
|
|
2023
Q3 | $1.04M | Buy |
17,409
+7,652
| +78% | +$504K | ﹤0.01% | 1635 |
|
|
2023
Q2 | $703K | Buy |
9,757
+6,900
| +242% | +$518K | ﹤0.01% | 1838 |
|
|
2023
Q1 | $210K | Sell |
2,857
-752
| -21% | -$53.5K | ﹤0.01% | 2234 |
|
|
2022
Q4 | $241K | Sell |
3,609
-40,225
| -92% | -$2.62M | ﹤0.01% | 2222 |
|
|
2022
Q3 | $2.35M | Sell |
43,834
-5,279
| -11% | -$310K | ﹤0.01% | 1412 |
|
|
2022
Q2 | $2.73M | Sell |
49,113
-5,179
| -10% | -$294K | ﹤0.01% | 1381 |
|
|
2022
Q1 | $3.43M | Buy |
54,292
+11,675
| +27% | +$847K | ﹤0.01% | 1357 |
|
|
2021
Q4 | $4.11M | Sell |
42,617
-10,785
| -20% | -$996K | ﹤0.01% | 1376 |
|
|
2021
Q3 | $4.64M | Sell |
53,402
-2,373
| -4% | -$184K | ﹤0.01% | 1353 |
|
|
2021
Q2 | $4.57M | Sell |
55,775
-6,194
| -10% | -$515K | ﹤0.01% | 1376 |
|
|
2021
Q1 | $5.89M | Buy |
61,969
+52,497
| +554% | +$4.96M | 0.01% | 1281 |
|
|
2020
Q4 | $588K | Sell |
9,472
-403,607
| -98% | -$23M | ﹤0.01% | 2001 |
|
|
2020
Q3 | $24.6M | Sell |
413,079
-24,269
| -6% | -$1.66M | 0.03% | 708 |
|
|
2020
Q2 | $30.5M | Sell |
437,348
-34,251
| -7% | -$2.17M | 0.04% | 610 |
|
|
2020
Q1 | $21.4M | Sell |
471,599
-13,041
| -3% | -$739K | 0.04% | 631 |
|
|
2019
Q4 | $31.5M | Sell |
484,640
-168,988
| -26% | -$11.3M | 0.04% | 655 |
|
|
2019
Q3 | $40.6M | Sell |
653,628
-287,069
| -31% | -$18M | 0.05% | 531 |
|
|
2019
Q2 | $67M | Sell |
940,697
-110,374
| -11% | -$8.13M | 0.14% | 217 |
|
|
2019
Q1 | $82.4M | Buy |
1,051,071
+298,302
| +40% | +$22.6M | 0.19% | 131 |
|
|
2018
Q4 | $63.7M | Buy |
752,769
+50,455
| +7% | +$5.38M | 0.16% | 170 |
|
|
2018
Q3 | $120M | Sell |
702,314
-159,066
| -18% | -$24M | 0.25% | 90 |
|
|
2018
Q2 | $111M | Buy |
861,380
+43,401
| +5% | +$4.84M | 0.24% | 95 |
|
|
2018
Q1 | $84.3M | Sell |
817,979
-28,104
| -3% | -$2.78M | 0.18% | 148 |
|
|
2017
Q4 | $72.3M | Sell |
846,083
-213,933
| -20% | -$18.5M | 0.15% | 190 |
|
|
2017
Q3 | $90M | Sell |
1,060,016
-28,333
| -3% | -$2.24M | 0.2% | 132 |
|
|
2017
Q2 | $82.4M | Sell |
1,088,349
-5,234
| -0.5% | -$366K | 0.19% | 137 |
|
|
2017
Q1 | $72.2M | Sell |
1,093,583
-453,732
| -29% | -$29.8M | 0.17% | 189 |
|
|
2016
Q4 | $98.1M | Buy |
1,547,315
+40,291
| +3% | +$2.54M | 0.25% | 94 |
|
|
2016
Q3 | $95.9M | Buy |
1,507,024
+1,506,133
| +169,038% | +$111M | 0.27% | 91 |
|
|
2016
Q2 | $66K | Buy |
891
+386
| +76% | +$28.6K | ﹤0.01% | 1442 |
|
|
2016
Q1 | $34K | Sell |
505
-397
| -44% | -$24.1K | ﹤0.01% | 1534 |
|
|
2015
Q4 | $61K | Sell |
902
-28
| -3% | -$1.73K | ﹤0.01% | 1508 |
|
|
2015
Q3 | $50K | Sell |
930
-112
| -11% | -$6.8K | ﹤0.01% | 1488 |
|
|
2015
Q2 | $65K | Buy |
+1,042
| New | +$56.9K | ﹤0.01% | 1389 |
|
Other funds holding LGND
JT
CAM
Victory Capital Management's LGND Position: Q2 2026 in Review
Victory Capital Management reduced its Ligand Pharmaceuticals (LGND) stake by 16% in Q2 2026, selling an estimated $11.7M and leaving 253,764 shares worth $80.2M. The position accounts for 0.05% of the portfolio, ranked #389.
Victory Capital Management first reported a position in LGND in Q2 2015 and has held it in 45 quarters since. The position peaked at $120M in Q3 2018. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Victory Capital Management held 253,764 shares of Ligand Pharmaceuticals worth $80.2M as of Q2 2026.
- Victory Capital Management sold 49,460 Ligand Pharmaceuticals shares in Q2 2026, an estimated $11.7M.
- Ligand Pharmaceuticals made up 0.05% of Victory Capital Management's portfolio in Q2 2026, its #389 holding.
- Victory Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2015 and has held it in 45 quarters since.
- Victory Capital Management's Ligand Pharmaceuticals position peaked at $120M in Q3 2018.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.